--- title: "What is Leerink Partnrs' Estimate for KYMR Q3 Earnings?" description: "Investment analysts at Leerink Partners have issued their Q3 2026 earnings estimates for Kymera Therapeutics, predicting an EPS of ($1.09). The consensus for the full year is ($2.79) per share. Other " type: "news" locale: "en" url: "https://longbridge.com/en/news/253236633.md" published_at: "2025-08-15T13:36:53.000Z" --- # What is Leerink Partnrs' Estimate for KYMR Q3 Earnings? > Investment analysts at Leerink Partners have issued their Q3 2026 earnings estimates for Kymera Therapeutics, predicting an EPS of ($1.09). The consensus for the full year is ($2.79) per share. Other brokerages have provided varying ratings and price targets, with an average target price of $59.11. Kymera's stock has seen a 5.4% increase, currently priced at $39.71, with a market cap of $2.59 billion. The company reported a loss of ($0.95) EPS for the last quarter, missing estimates, and revenue decreased by 55.1% year-over-year. - Analysts Can't Get Enough of These Little-Known Biopharma Stocks Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($1.09) for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.11) EPS. A number of other brokerages have also recently commented on KYMR. Oppenheimer reissued an "outperform" rating and issued a $53.00 price objective (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 25th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price target for the company. Finally, Wells Fargo & Company dropped their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $59.11. Get **Kymera Therapeutics** alerts: **Get Our Latest Stock Analysis on Kymera Therapeutics** ## Kymera Therapeutics Stock Up 5.4% Shares of NASDAQ:KYMR opened at $39.71 on Wednesday. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $53.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of -11.54 and a beta of 2.18. The firm has a fifty day simple moving average of $44.93 and a two-hundred day simple moving average of $36.45. Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 32.86%. The business's revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. ## Insider Buying and Selling at Kymera Therapeutics In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by company insiders. ## Institutional Inflows and Outflows Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its stake in shares of Kymera Therapeutics by 30.3% in the fourth quarter. Franklin Resources Inc. now owns 38,367 shares of the company's stock worth $1,544,000 after acquiring an additional 8,927 shares during the period. Geode Capital Management LLC increased its stake in shares of Kymera Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after acquiring an additional 52,263 shares during the period. Wells Fargo & Company MN increased its stake in shares of Kymera Therapeutics by 51.8% in the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after acquiring an additional 7,487 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter worth $1,609,000. ## Kymera Therapeutics Company Profile (Get Free Report) Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. ## Read More - Five stocks we like better than Kymera Therapeutics - How to Start Investing in Real Estate - Data Centers in Demand—This REIT Owns a Whole Portfolio - Stock Average Calculator - 3 Battery Stocks to Buy and Hold for the Rest of the Decade - What is the Nikkei 225 index? - 3 Stocks to Consider as Tension Builds in Energy Markets *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Kymera Therapeutics Right Now? Before you consider Kymera Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list. While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [KYMR.US - Kymera Therapeutics](https://longbridge.com/en/quote/KYMR.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 在 KT-621 试验更新以及摩根大通会议的关注之后，审视 Kymera Therapeutics（KYMR）的估值 | Kymera Therapeutics (KYMR) 由于其 KT-621 试验中积极的 STAT6 降解数据以及对摩根大通医疗会议的期待而受到关注。该股票目前价格为 74.77 美元，反映出过去一个月下降了 16.63%，但在过去一年中上 | [Link](https://longbridge.com/en/news/272188431.md) | | Kymera Therapeutics 宣布了其 2026 年战略，旨在推进口服免疫学管线，推出新的开发候选药物，并启动关键的临床试验 | Kymera Therapeutics Inc. 宣布了其 2026 年战略，以推进其口服免疫学管线，包括计划于 2026 年第一季度开始的 KT-579 的第一阶段临床试验。该公司旨在推动至少一个新的开发候选药物向 IND 申请迈进。正在 | [Link](https://longbridge.com/en/news/272408842.md) | | Kymera Therapeutics 在摩根大通医疗健康大会上公布 2026 年目标 | Kymera Therapeutics Inc. 在摩根大通医疗会议上展示了其 2026 年的目标，概述了其口服免疫学管线的临床前和临床里程碑。该公司强调了其财务实力，拥有 16 亿美元的现金，确保了其运营资金可持续到 2029 年。此次演 | [Link](https://longbridge.com/en/news/272407486.md) | | Kymera Therapeutics (KYMR) 的快速通道 KT-621 更新对股东的意义是什么 | Kymera Therapeutics 已获得 FDA 快速通道认证，用于治疗特应性皮炎的 KT-621，并正在为 2026 年的 2b 期哮喘试验做准备。该公司专注于其免疫学管线，包括 IRAK4、STAT6 和 TYK2 项目。投资者情 | [Link](https://longbridge.com/en/news/271962951.md) | | Kymera Therapeutics 将参与古根海姆生物技术峰会和奥本海默医疗保健会议 | Kymera Therapeutics Inc. 将于 2 月 11 日上午 9:00（东部时间）参加 Guggenheim 新兴前景：生物技术峰会 2026，并于 2 月 26 日下午 2:00（东部时间）参加 Oppenheimer 第 | [Link](https://longbridge.com/en/news/274807457.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.